Revascularization Strategy in Myocardial Infarction with Multivessel Disease.
Alexander JobsSteffen DeschAnne FreundHans-Josef FeistritzerHolger ThielePublished in: Journal of clinical medicine (2024)
The proportion of patients with multivessel coronary artery disease in individuals experiencing acute coronary syndrome (ACS) varies based on age and ACS subtype. In patients with ST-segment elevation myocardial infarction (STEMI) without cardiogenic shock, the prognostic benefit of complete revascularization has been demonstrated by several randomized trials and meta-analyses, leading to a strong guideline recommendation. However, similar data are lacking for ACS without ST-segment elevation (NSTE-ACS). Non-randomized data suggesting a benefit from complete revascularization in non-ST-segment elevation myocardial infarction (NSTEMI) are prone to selection bias and should be interpreted with caution. A series of large randomized controlled trials have been initiated recently to address these open questions.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- st segment elevation myocardial infarction
- coronary artery bypass grafting
- st elevation myocardial infarction
- antiplatelet therapy
- meta analyses
- coronary artery disease
- randomized controlled trial
- electronic health record
- systematic review
- coronary artery bypass
- big data
- heart failure
- double blind
- open label
- minimally invasive
- left ventricular
- data analysis
- placebo controlled
- clinical trial
- phase iii
- artificial intelligence
- aortic valve
- deep learning
- cardiovascular events
- study protocol